Lifestyle changes for prehypertension with other cardiovascular risk factors: Findings from Thailand

Journal of the American Pharmacists Association

Volumn 51, Issue 6, 2011, Pages 719-726

  Pongwecharak, Juraporn ^a   Treeranurat, Tarakamon ^b  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

^b Faculty of Science and Technology   (Thailand)

Author keywords

Health screening; Hypertension; Patient education; Pharmacy services; Prehypertension; Risk factors (cardiovascular); Thailand

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DESCRIPTIVE RESEARCH; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; EXERCISE; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT REFERRAL; PHARMACIST; PHARMACY; PREHYPERTENSION; SMOKING; SYSTOLIC BLOOD PRESSURE; THAILAND; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HOSPITAL INFORMATION SYSTEM; HYPERTENSION; LIFESTYLE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; PROFESSIONAL STANDARD; RISK FACTOR;

ADULT; CARDIOVASCULAR DISEASES; COMMUNITY PHARMACY SERVICES; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LIFE STYLE; MALE; MASS SCREENING; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PHARMACISTS; POINT-OF-CARE SYSTEMS; PREHYPERTENSION; PROFESSIONAL ROLE; RISK FACTORS; THAILAND;

EID: 84857478387     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2011.10129     Document Type: Article

References (32)

1. Thailand Ministry of Public Health. Health status and health problems of Thai people. In: Thailand health profile report 2005-2007. Accessed at www.moph.go.th/ops/thp/index.php, November 30, 2009.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52.
3. Aekplakorn W, Abbott-Klafter J, Khonputsa P, et al. Prevalence and management of prehypertension and hypertension by geographic regions of Thailand: the Third National Health Examination Survey, 2004. J Hypertens. 2008;26:191-8.
4. Greenlund KJ, Croft JB, Mensah GA. Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000. Arch Intern Med. 2004;164:2113-8.
5. Kshisagar AV, Carpenter M, Bang H, et al. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med. 2006;119:133-41.
6. Conen D, Ridker PM, Buring JE, Glynn RJ. Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. BMJ. 2007;335:432.
7. Lawes CM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21:707-16.
8. Gu D, Kelly TN, Wu X, et al. Blood pressure and risk of cardiovascular disease in Chinese men and women. Am J Hypertens. 2008;21:265-72.
9. Ikeda A, Iso H, Yamagishi K, et al. Blood pressure and the risk of stroke, cardiovascular disease, and all-cause mortality among Japanese: the JPHC study. Am J Hypertens. 2009;22:273-80.
10. Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005;365:434-41.
11. Nash IS. Reassessing normal blood pressure. BMJ. 2007;335:408-9.
12. Lee J, Ma S, Heng D, et al. Hypertension, concurrent cardiovascular risk factors and mortality: the Singapore Cardiovascular Cohort Study. J Hum Hypertens. 2008;22:468-74.
13. Pongwecharak J, Treeranurat T. Screening for pre-hypertension and elevated cardiovascular risk factors in a Thai community pharmacy. Pharm World Sci. 2010; 32:329-33.
14. Zimmerman GL, Olsen CG, Bosworth MF. A 'stages of change' approach to helping patients change behavior. Am Fam Physician. 2000;61:1409-16.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31(suppl 1):S55-60.
16. Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens. 2008;26:1505-30.
17. Karwalajtys T, Kaczorowski J, Hutchison B, et al. Blood pressure variability and prevalence of hypertension using automated readings from multiple visits to a pharmacy-based community-wide programme. J Hum Hypertens. 2009;23:585-9.
18. International Diabetes Federation. Global guideline for type 2 diabetes. Accessed at www.idf.org/webdata/docs/IDF%20GGT2D.pdf, November 19, 2009.
19. Krass I, Mitchell B, Clarke P, et al. Pharmacy diabetes care program: analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy. Diabetes Res Clin Pract. 2007;75:339-47.
20. Hoerger TJ, Harris R, Hicks KA, et al. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med. 2004;140:689-99.
21. Waugh N, Scotland G, McNamee P, et al. Screening for type 2 diabetes: literature review and economic modeling. Accessed at www.hta.ac.uk/execsumm/ summ1117.shtml, November 1, 2009.
22. Snella KA, Canales AE, Irons BK, et al. Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high-risk individuals. J Am Pharm Assoc. 2006;46:370-7.
23. Liu Y, McDonough RP, Carruthers KM, Doucette WR. Identifying patients at risk of cardiovascular disease: a pharmacist-managed screening event for union workers and their dependents. J Am Pharm Assoc. 2009;49:549-53.
24. Horgan JM, Blenkinsopp A, McManus RJ. Evaluation of a cardiovascular disease opportunities risk assessment pilot ('Heart MOT' service) in community pharmacies. J Public Health (Oxf). 2010;32:110-6.
25. Peterson GM, Fitzmaurice KD, Kruup H, et al. Cardiovascular risk screening program in Australian community pharmacies. Pharm World Sci. 2010;32:373-80.
26. Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviors and risk factors for coronary heart disease. J Public Health Med. 2003;25:144-53.
27. Yamada C, Johnson JA, Robertson P, et al. Long term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: extended follow-up of the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Pharmacotherapy. 2005;25:110-5.
28. Chiang CE, Chen CH. Hypertension in the Asia-Pacific region. J Hum Hypertens. 2008;22:441-3.
29. National Statistical Office of Thailand. The 2007 cigarette smoking and alcoholic drinking behaviour survey. Accessed at http://web.nso.go.th/survey/ smoke/smoke07.htm, November 19, 2009.
30. Botomino A, Bruppacher R, Krähenbühl S, Hersberger KE. Change of body weight and lifestyle of persons at risk for diabetes after screening and counseling in pharmacies. Pharm World Sci. 2008;30:222-6.
31. Olenak JL, Calpin M. Establishing a cardiovascular health and wellness program in a community pharmacy: screening for metabolic syndrome. J Am Pharm Assoc. 2010;50:32-6.
32. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:948-54.